# TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

> **NCT05948813** · PHASE2 · RECRUITING · sponsor: **TYK Medicines, Inc** · enrollment: 420 (estimated)

## Conditions studied

- NSCLC
- EGFR Activating Mutation
- Brain Metastases

## Interventions

- **DRUG:** TY-9591
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT05948813
- **Lead sponsor:** TYK Medicines, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-17
- **Primary completion:** 2025-06-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05948813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05948813, "TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05948813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*